Floatz logo

Silicon Phthalocyanine 4

Stage IIA Mycosis Fungoides/Sezary Syndrome

Kevin Cooper MDPhase 1Dormant
CC
46/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
31/ 100
Competitive Position
95/ 100

Competitive context

6 Active assets in the Stage IIA Mycosis Fungoides/Sezary Syndrome cohort.

Asset / SponsorPhaseRating
Romidepsin
Northwestern University
Phase 2BB
Fludarabine
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Phase 2BB
Pembrolizumab
University of Michigan Rogel Cancer Center
Phase 2BB
TACROLIMUS
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Phase 2B
MOGAMULIZUMAB
University of Michigan Rogel Cancer Center
Phase 2B

View all 29 →

Same molecule, other indications

Silicon Phthalocyanine 4 is also rated in:

skin carcinomaDormant
CC
Indicative ·
46 / 100
View asset →
precancerous conditionDormant
CC
Indicative ·
46 / 100
View asset →
mycosis fungoidesDormant
CC
Indicative ·
46 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →